Choosing BTKi or BCL2i or Combination Therapy for 1L CLL

Danielle Brander

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Oncologists' Perspectives on the Effects of Time Toxicity in Cancer …

Safiya Karim

ASH 2024 Insights: POLARIX 5yr Update - Pola-R-CHP vs. R-CHOP in 1L …

2024 ASH Annual Meeting Insights Hub

G. Salles

Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

Current Treatment of 1L Hodgkin Lymphoma

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

ASH 2024 Insights: Incorporating Nivolumab and Brentuximab Vedotin I…

2024 ASH Annual Meeting Insights Hub

A. LaCasce

2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

1L Therapy in CLL: What Are the Best Options?

SOHO Brazil 2024

J. Burger

ESMO 2024 Summary: The Emerging Global Epidemic of Early-Onset Cance…

2024 ESMO Annual Meeting Insights Hub

S. Ogino

Year in Review 2024: CLL Highlights

The University of Kansas Cancer Center

M. Hoffmann

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Sequencing Cellular Therapy and Bispecific Antibodies in DLBCL

Megan Melody

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

Treating Patients With DLBCL Who Are Not Eligible for CAR-T Therapy

Remy Dulery

Chemotherapy-Induced Hair Loss: Insights and Effective Strategies

Masonic Cancer Center, University of Minnesota

M. Hordinsky

Debates in CLL: Continuous or Finite Duration Therapy

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

Overview of CNS Cancers

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

V. Venur